These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 29271954)

  • 1. [Engineering Antibodies as Drugs: Principles and Practice].
    Lugovskoy AA
    Mol Biol (Mosk); 2017; 51(6):886-898. PubMed ID: 29271954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Next-Generation Techniques for Discovering Human Monoclonal Antibodies].
    Lushova AA; Biazrova MG; Prilipov AG; Sadykova GK; Kopylov TA; Filatov AV
    Mol Biol (Mosk); 2017; 51(6):899-906. PubMed ID: 29271955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antibody-Based Drugs and Other Recombinant Proteins for Diagnostics and Therapy of Viral Infections, Autoimmune Diseases and Cancer].
    Kuprash DV; Garib FY; Nedospasov SA
    Mol Biol (Mosk); 2017; 51(6):883-885. PubMed ID: 29271953
    [No Abstract]   [Full Text] [Related]  

  • 4. [Targeted Bifunctional Proteins and Hybrid Nanoconstructs for Cancer Diagnostics and Therapies].
    Deyev SM; Lebedenko EN
    Mol Biol (Mosk); 2017; 51(6):907-926. PubMed ID: 29271956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.
    Vincent KJ; Zurini M
    Biotechnol J; 2012 Dec; 7(12):1444-50. PubMed ID: 23125076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges.
    Teillaud JL
    Expert Opin Biol Ther; 2005 Sep; 5 Suppl 1():S15-27. PubMed ID: 16187937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology.
    Niwa R; Satoh M
    J Pharm Sci; 2015 Mar; 104(3):930-41. PubMed ID: 25583555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations.
    Shim H
    Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next generation antibody drugs: pursuit of the 'high-hanging fruit'.
    Carter PJ; Lazar GA
    Nat Rev Drug Discov; 2018 Mar; 17(3):197-223. PubMed ID: 29192287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of humanized antibodies as cancer therapeutics.
    Qu Z; Griffiths GL; Wegener WA; Chang CH; Govindan SV; Horak ID; Hansen HJ; Goldenberg DM
    Methods; 2005 May; 36(1):84-95. PubMed ID: 15848077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering antibodies for therapy.
    Presta LG
    Curr Pharm Biotechnol; 2002 Sep; 3(3):237-56. PubMed ID: 12164480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homogeneously modified immunoglobulin domains for therapeutic application.
    Liu T; Du J; Luo X; Schultz PG; Wang F
    Curr Opin Chem Biol; 2015 Oct; 28():66-74. PubMed ID: 26117722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific antibodies for cancer therapy.
    Hollander N
    Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-targeted RNase fusion proteins (immunoRNases) for cancer therapy.
    Krauss J; Arndt MA; Dübel S; Rybak SM
    Curr Pharm Biotechnol; 2008 Jun; 9(3):231-4. PubMed ID: 18673289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antibody Engineering: From the Idea to Its Implementation].
    Polanovsky OL
    Mol Biol (Mosk); 2017; 51(6):1039-1045. PubMed ID: 29271966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving the efficacy of antibody-based cancer therapies.
    Carter P
    Nat Rev Cancer; 2001 Nov; 1(2):118-29. PubMed ID: 11905803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugates and bispecific T-cell engagers.
    Paci A; Desnoyer A; Delahousse J; Blondel L; Maritaz C; Chaput N; Mir O; Broutin S
    Eur J Cancer; 2020 Mar; 128():107-118. PubMed ID: 32037061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic antibodies and antibody fusion proteins.
    Rohrbach P; Broders O; Toleikis L; Dübel S
    Biotechnol Genet Eng Rev; 2003; 20():137-63. PubMed ID: 14997850
    [No Abstract]   [Full Text] [Related]  

  • 19. Antibody fragments for controlled delivery of therapeutic agents.
    Verhoeyen ME; van der Logt CP; Beggs TS; Davis PJ
    Biochem Soc Trans; 1995 Nov; 23(4):1067-73. PubMed ID: 8654683
    [No Abstract]   [Full Text] [Related]  

  • 20. Methods for generating multivalent and bispecific antibody fragments.
    Tomlinson I; Holliger P
    Methods Enzymol; 2000; 326():461-79. PubMed ID: 11036658
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.